ATE79039T1 - Nasale formulierungen und verfahren zu deren herstellung. - Google Patents

Nasale formulierungen und verfahren zu deren herstellung.

Info

Publication number
ATE79039T1
ATE79039T1 AT87311054T AT87311054T ATE79039T1 AT E79039 T1 ATE79039 T1 AT E79039T1 AT 87311054 T AT87311054 T AT 87311054T AT 87311054 T AT87311054 T AT 87311054T AT E79039 T1 ATE79039 T1 AT E79039T1
Authority
AT
Austria
Prior art keywords
production
methods
nasal formulations
phosphalidylcholine
phospholipid
Prior art date
Application number
AT87311054T
Other languages
English (en)
Inventor
Philip Edgar Hansen
Anders Robert Sorensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK604286A external-priority patent/DK604286D0/da
Priority claimed from DK370087A external-priority patent/DK370087D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE79039T1 publication Critical patent/ATE79039T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87311054T 1986-12-16 1987-12-15 Nasale formulierungen und verfahren zu deren herstellung. ATE79039T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK604286A DK604286D0 (da) 1986-12-16 1986-12-16 Praeparat
DK370087A DK370087D0 (da) 1987-07-16 1987-07-16 Produkt med forbedrede egenskaber
EP87311054A EP0272097B1 (de) 1986-12-16 1987-12-15 Nasale Formulierungen und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
ATE79039T1 true ATE79039T1 (de) 1992-08-15

Family

ID=26067181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87311054T ATE79039T1 (de) 1986-12-16 1987-12-15 Nasale formulierungen und verfahren zu deren herstellung.

Country Status (22)

Country Link
EP (1) EP0272097B1 (de)
JP (1) JPH0768149B2 (de)
KR (1) KR890700036A (de)
CN (1) CN1034105C (de)
AT (1) ATE79039T1 (de)
AU (1) AU606121B2 (de)
CA (1) CA1326210C (de)
CS (1) CS273139B1 (de)
DE (1) DE3780925T2 (de)
ES (1) ES2044957T3 (de)
FI (1) FI94024C (de)
GR (1) GR3005381T3 (de)
HU (1) HU209247B (de)
IE (1) IE61110B1 (de)
IL (1) IL84835A (de)
MX (1) MX9203640A (de)
NO (1) NO175566C (de)
NZ (1) NZ222907A (de)
PT (1) PT86370B (de)
RU (1) RU1837869C (de)
WO (1) WO1988004556A1 (de)
YU (1) YU46978B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
EP0308181A1 (de) * 1987-09-14 1989-03-22 Novo Nordisk A/S Transmucosale Formulierungen und Verfahren zu ihrer Herstellung
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
ES2061688T3 (es) * 1987-11-13 1994-12-16 Smithkline Beecham Farma Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
DE69027022T2 (de) * 1989-02-17 1996-11-28 Liposome Co Inc Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
CA2094217A1 (en) * 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
DE4214953C2 (de) * 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
DE4218291A1 (de) * 1992-06-03 1993-12-09 Mattern Et Partner Pharmazeuti Dosierspray für pernasale Applikation
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
AU689217B2 (en) 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5958379A (en) * 1994-09-30 1999-09-28 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh Pharmaceutical composition
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
EP1840134B1 (de) 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 Derivate
EP1060191B1 (de) 1998-02-27 2010-04-28 Novo Nordisk A/S Abkömmlinge von glp-1 analogen
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
EP1932535A3 (de) 1998-07-31 2008-10-29 Novo Nordisk A/S Anregung der Beta-Zellbildung
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US7087215B2 (en) 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6849263B2 (en) 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
DE60114996T2 (de) 2000-03-08 2006-08-10 Novo Nordisk A/S Senkung des serum cholesterols
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
TWI331522B (en) * 2001-06-22 2010-10-11 Cpex Pharmaceuticals Inc Pharmaceutical composition
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1660531A2 (de) 2003-08-05 2006-05-31 Novo Nordisk A/S Neue insulinderivate
SI2107069T1 (sl) 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP4792457B2 (ja) 2004-03-26 2011-10-12 ユニヴァーシタ’デグリ ステュディ ディ パルマ 高度に呼吸に適したインスリンのマイクロ粒子
CN1299770C (zh) * 2004-05-31 2007-02-14 刘近周 多功能鼻腔和鼻窦洁疗液
EP2769990A3 (de) 2004-12-02 2015-02-25 Domantis Limited Bispezifische Domänen-Antikörper gegen Serum Albumin und GLP-1 oder PYY
JP5410020B2 (ja) 2005-02-02 2014-02-05 ノヴォ ノルディスク アー／エス インスリン誘導体
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
ATE482977T1 (de) 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
JP5269766B2 (ja) 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
EP2386572B1 (de) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulinderivat
US20100216691A1 (en) 2007-07-16 2010-08-26 Novo Nordisk A/S Protease Stabilized, Pegylated Insulin Analogues
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
EP2262539B1 (de) 2008-04-01 2015-07-15 Novo Nordisk A/S Insulin-albumin-konzentrate
US8551454B2 (en) 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8277781B2 (en) 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
EP2411054A2 (de) 2009-03-27 2012-02-01 Glaxo Group Limited Arzneifusionen und konjugate
JP2013506628A (ja) 2009-09-30 2013-02-28 グラクソ グループ リミテッド 延長された半減期を有する薬物融合物及びコンジュゲート
MX366314B (es) 2010-10-27 2019-07-05 Novo Nordisk As Uso de derivados de insulina por inyecciones con intervalos variables.
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
EP2788027A2 (de) 2011-12-09 2014-10-15 Novo Nordisk A/S Glp-1-agonisten
MX363119B (es) 2012-05-01 2019-03-11 Novo Nordisk As Composicion farmaceutica.
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
RS59918B2 (sr) * 2015-02-17 2023-01-31 Lilly Co Eli Nazalna praškasta formulacija za tretman hipoglikemije
EP3873434A1 (de) 2018-11-04 2021-09-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nasale zusammensetzungen und verfahren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
GB8327330D0 (en) * 1983-10-12 1983-11-16 Parsons W J Membrane analogue emulsions
EP0179904A1 (de) * 1984-05-09 1986-05-07 Medaphore Inc. Orales insulin und verfahren zu seiner herstellung
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
IL78425A (en) * 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
IT1187743B (it) * 1985-09-26 1987-12-23 Prodotti Formenti Srl Composizioni farmaceutiche a base di destrorfano per applicazione instranasale

Also Published As

Publication number Publication date
CS273139B1 (en) 1991-03-12
DE3780925T2 (de) 1992-12-24
WO1988004556A1 (en) 1988-06-30
IE61110B1 (en) 1994-10-05
IL84835A0 (en) 1988-06-30
CN87108340A (zh) 1988-07-13
EP0272097B1 (de) 1992-08-05
NO175566B (no) 1994-07-25
MX9203640A (es) 1992-09-01
AU1085888A (en) 1988-07-15
CS930487A1 (en) 1990-07-12
NO883627L (no) 1988-08-15
CA1326210C (en) 1994-01-18
FI883783A0 (fi) 1988-08-15
EP0272097A3 (en) 1988-08-24
NO175566C (no) 1994-11-02
FI94024B (fi) 1995-03-31
CN1034105C (zh) 1997-02-26
IE873408L (en) 1988-06-16
ES2044957T3 (es) 1994-01-16
PT86370A (en) 1988-01-01
FI883783A (fi) 1988-08-15
NO883627D0 (no) 1988-08-15
PT86370B (pt) 1990-11-20
IL84835A (en) 1994-01-25
EP0272097A2 (de) 1988-06-22
DE3780925D1 (de) 1992-09-10
KR890700036A (ko) 1989-03-02
NZ222907A (en) 1990-08-28
YU46978B (sh) 1994-09-09
JPH01501550A (ja) 1989-06-01
YU228487A (en) 1988-12-31
HUT57592A (en) 1991-12-30
HU209247B (en) 1994-04-28
FI94024C (fi) 1995-07-10
RU1837869C (ru) 1993-08-30
GR3005381T3 (de) 1993-05-24
AU606121B2 (en) 1991-01-31
JPH0768149B2 (ja) 1995-07-26

Similar Documents

Publication Publication Date Title
ATE79039T1 (de) Nasale formulierungen und verfahren zu deren herstellung.
DE3671367D1 (de) Arzneistoffadsorbate und deren herstellung.
FI871750A0 (fi) Nasal administration av laekemedel.
DE68929422D1 (de) Nukleophile polysubstituierte Arylacridiniumester, deren Konjugate, sowie deren Herstellung und Verwendungen
ATE109971T1 (de) Verabreichung von arzneimitteln über die lungen.
NL193340B (nl) Farmaceutisch preparaat voor parenterale toediening gevormd uit een vetemulsie.
FR2578540B1 (fr) Nouveaux derives de pyridylmethoxy- et -methylmercaptoanilines, utilses notamment comme antiasthmatiques, leur fabrication et medicaments les contenant
FI950909A (fi) Rasvahappojohdannaisia
SE8800080D0 (sv) Lekemedelskomposition
DE3777367D1 (de) Hirudin-variante, deren verwendung und herstellung.
DE3673587D1 (de) Magnetronanode und deren herstellung.
DE3675722D1 (de) 4-alkoxy-3-pyrrolin-2-on-1-yl-essigsaeurealkyl- bzw. -benzylester sowie deren herstellung.
DE3774847D1 (de) Trifluorhydroxyaromatische saeure und deren herstellung.
DE3786927D1 (de) Antithrombotische arzneimittel und deren herstellung.
ES541944A0 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
DE3853079D1 (de) Liposome hoher stabilität und verfahren zur herstellung und verwendung.
EP0265338A3 (en) Stable therapeutical compositions based on hydrophobic vegetable oil, and process for preparing them
DE3687170D1 (de) Antitumorale antibiotika und deren herstellung.
DE3583015D1 (de) Phospholipidkonjugate und deren herstellung.
DE3881812D1 (de) Physiologisch aktive substanzen, probestin und prostatin und deren herstellung.
DE3764233D1 (de) Cyclopentylaether, deren herstellung und pharmazeutische formulierung.
ATE58527T1 (de) 4-alkoxy-3-pyrrolin-2-on-1-yl-essigsaeurealkylbzw. -benzylester sowie deren herstellung.
ATE59390T1 (de) Askorbat-2-polyphosphatester und deren herstellung.
DE3675747D1 (de) 1,4-dihydropyridinverbindungen und ihre herstellung und pharmazeutische formulierung.
ATE58530T1 (de) 1,4-dihydropyridinverbindungen und ihre herstellung und pharmazeutische formulierung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee